FDA Rejects Over 889,000 Tobacco Applications for Noncompliance

Oct.17.2022
FDA Rejects Over 889,000 Tobacco Applications for Noncompliance
FDA rejects 889,000 tobacco product applications while accepting over 1,600, mostly for e-cigarettes and e-liquids. Warning letters sent to manufacturers and retailers.

The US Food and Drug Administration (FDA) has announced that it has issued more than 889,000 Refuse to Accept (RTA) letters as of October 7, to pre-market tobacco product applications (PMTAs) that do not meet acceptance criteria.


The organization also announced that the FDA has received over 1,600 applications, the majority of which are for electronic cigarettes or e-liquid products.


Although the review process is ongoing, the FDA remains vigilant in regulating the market and will continue to use our compliance and enforcement resources to curb the illegal marketing of non-tobacco nicotine products. To date, the FDA has issued more than 60 warning letters to manufacturers, including popular brands among young people such as Puff Bar," stated the FDA in a press release. "The warning letters include products that have submitted applications but have received negative actions from the agency.


The FDA has sent over 300 warning letters to retailers demanding that they cease selling synthetic nicotine e-cigarette products to minors, and has imposed civil fines on two retailers for selling e-cigarette products to minors.


So far, the FDA has not authorized any synthetic nicotine e-cigarette products. Therefore, all synthetic nicotine e-cigarette products on the market are being sold illegally and are at risk of FDA enforcement action," said the FDA. "Retailers or distributors selling or distributing unauthorized e-cigarettes are breaking the law and those engaging in such behavior will face FDA enforcement risks, such as seizures, injunctions, or civil fines.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of the content. The translation of this article is solely for industry exchange and research purposes.


Due to limitations in our translation abilities, the translated article may not fully represent the original text. Therefore, please refer to the original text for accurate information.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The ownership of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.
Special Report
Feb.23
China’s tobacco regulator names Yao Laiying as top leader
China’s tobacco regulator names Yao Laiying as top leader
China’s tobacco regulator has undergone a top leadership change, according to an official announcement on March 20.
Mar.20
Casey’s, the No. 3 U.S. C-Store Chain, Sees Nicotine Category Shift as Pouches Rise 31% and Vapor 12%
Casey’s, the No. 3 U.S. C-Store Chain, Sees Nicotine Category Shift as Pouches Rise 31% and Vapor 12%
Casey’s General Stores (NASDAQ: CASY) reported accelerating growth in modern nicotine products during its fiscal third quarter ended January 31, 2026. Nicotine pouch sales increased 31% year over year, while vapor products rose 12%. Although cigarette unit sales continued to decline, management stated that the rate of decline slowed compared to prior quarters.
Market
Mar.15
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11